Lung cancer drug trial stopped early due to lack of participants

NCT ID NCT04926831

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times

Summary

This study aimed to see if the drug capmatinib, given before and after surgery, could improve outcomes for people with early-stage non-small cell lung cancer that has a specific genetic change (MET mutation). Only 4 people enrolled, and the trial was stopped early, so we don't have enough information to know if the treatment works. The study was for adults with stage IB to IIIB lung cancer suitable for surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Fairfax Northern Virginia Hem Onc

Fairfax, Virginia, 22031, United States
Fairfax Northern Virginia Hem Onc .

Fairfax, Virginia, 22031, United States
UCLA Oncology Hematology

La Jolla, California, 92037, United States
UCLA Oncology Hematology .

La Jolla, California, 92037, United States
University of California Davis Cancer Center

Sacramento, California, 95817, United States
University of California Davis Cancer Center .

Sacramento, California, 95817, United States

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER